DDInter1008 DDInter660
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .
Ketoconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eravacycline
Ketoconazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Eravacycline
Ketoconazole {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eravacycline
Ketoconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eravacycline
Ketoconazole {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eravacycline
Ketoconazole {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Mycophenolic acid
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eravacycline
Ketoconazole {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Eravacycline
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eravacycline
Ketoconazole {u} (Compound) upregulates {v} (Gene) ALDOC
ALDOC {u} (Gene) is upregulated by {v} (Compound) Mycophenolic acid
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eravacycline
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eravacycline
Ketoconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Eravacycline
Ketoconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Eravacycline
Ketoconazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Eravacycline
Ketoconazole (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Clarithromycin (Compound) and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Eravacycline
Ketoconazole (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Eravacycline
Ketoconazole (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Mycophenolic acid (Compound) and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Eravacycline
Ketoconazole (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may lead to a major life threatening interaction when taken with Eravacycline
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Eravacycline
Ketoconazole (Compound) upregulates ALDOC (Gene) and ALDOC (Gene) is upregulated by Mycophenolic acid (Compound) and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Eravacycline
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Eravacycline